Nycomed and ZLB Behring today announced the signing of a ten-year market and distribution agreement for Beriplast® P Combi-Set, a wound healing product manufactured by ZLB Behring......
The financial results reported in this release are related to the fully-owned Nycomed subsidiary, Nyco Holdings 2 ApS, which through its subsidiaries and affiliates, comprises all of the Nycomed Group’s operations......
Nycomed has launched Angiox™ (bivalirudin), first in a new generation of anticoagulants approved for Europe. From today, Angiox™ is available in Austria, Denmark, Finland, Germany and Sweden, and will be launched throughout Europe in the coming months......
Nycomed has, together with its US collaborator The Medicines Company (Nasdaq: MDCO), successfully achieved EU marketing authorisation for a new cardiovascular product, Angiox™ (bivalirudin), which will be marketed by Nycomed......
The financial results reported in this release are related to the fully-owned Nycomed subsidiary, Nyco Holdings 2 ApS, which through its subsidiaries and affiliates comprises all of the Nycomed Group’s operations......
Clinical trial data has confirmed the efficacy and safety of ZyComb™, a new combination nasal spray for the simultaneous treatment of the two major symptoms of common cold – nasal congestion and runny nose......
Nycomed announced today, 7 July 2004, that it has entered into a collaboration, license and supply agreement with Acusphere Inc (NASDAQ: ACUS) granting Nycomed the rights to develop and market Acusphere's lead product candidate, AI-700, in Europe, including the Commonwealth of Independent States (CIS) and Turkey......
Nycomed has together with its US collaborator, The Medicines Company (Nasdaq:MDCO), successfully reached a milestone in the European registration process of Angiox™ (bivalirudin)......
The European Commission has issued an EU marketing authorisation (MA) for Nycomed’s new surgical product TachoSil™. This decision follows the Agency for the Evaluation of Medicinal Products’ (EMEA) announcement on 27 February of a positive scientific assessment for TachoSil™......
Nycomed has established sales offices in Warsaw, Poland, thereby entering the Polish market for pharmaceutical products. The Polish office opens officially today, 18 May 2004......
The financial results reported in this release are related to the fully-owned Nycomed subsidiary, Nyco Holdings 2 ApS, which through its subsidiaries and affiliates comprises all of the Nycomed Group’s operations......
Salt Lake City, Utah and Roskilde, Denmark, 21. April 2004, NPS Pharmaceuticals Inc (Nasdaq: NPSP) and Nycomed Group today announced that they have signed a distribution and license agreement granting Nycomed rights to develop and market the investigational osteoporosis drug PREOS® in Europe, including the Commonwealth of Independent States (CIS) and Turkey......
The financial results reported in this release are related to the parent company, Nyco Holdings ApS. The full annual report is available under Company Reports in the Investors section on www......
Nycomed has successfully reached a milestone in the European registration process of TachoSil™. As part of the Centralised Procedure under the European Agency for the Evaluation of Medicinal Products (EMEA), the scientific assessment report is now available to Nycomed......
To improve the co-ordination of our marketing & sales activities across Europe, including Russia/CIS, a new European organisation has been implemented. The new marketing & sales organisation will include all European subsidiaries, which will now report to Timo Tiivola, SVP, Head of Marketing & Sales......